Non-LDL-related dyslipidaemia and coronary risk: a case-control study

Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease
Gerd AssmannHelmut Schulte

Abstract

To assess the non-LDL-C-related dyslipidaemia risk of MI, 823 men aged 23 to 65 with a first MI were compared with 823 MI-free PROCAM controls matched for sex, age, smoking, DM, BP and LDL-C. Overall, the odds of MI in men with HDL-C < 1.15 mmol/L were 2.6 times those of men with HDL-C >or= 1.15 mmol/L, and the odds of MI in men with triglycerides >or= 1.71 mmol/L were 1.4 times those of men with lower triglycerides. If LDL-C was < 2.58 mmol/L, relative MI odds attributed to HDL-C < 1.15 mmol/L increased to 3.4, while relative odds attributed to triglycerides >or= 1.71 mmol/L increased to 2.6; men in this LDL category with HDL-C < 1.15 mmol/L and/or triglycerides >or= 1.71 mmol/L displayed an MI odds ratio of 5.0. MI risk associated with low HDL-C and/or high triglycerides is substantial, particularly if LDL-C is low.

References

Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Sep 1, 1968·Clinica Chimica Acta; International Journal of Clinical Chemistry·C Glatz, G A Rose
Apr 29, 1998·BMJ : British Medical Journal·H T DaviesM Tavakoli
Aug 6, 2000·Stroke; a Journal of Cerebral Circulation·S G WannametheeS Ebrahim
May 26, 2001·The Journal of Endocrinology·P DeleriveB Staels
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Oct 20, 2004·Circulation·A PatelUNKNOWN Asia Pacific Cohort Studies Collaboration
Nov 17, 2004·Current Pharmaceutical Design·A J JenkinsR L Klein
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Nov 27, 2007·Journal of the American College of Cardiology·Earl S Ford, Simon Capewell
Jan 10, 2008·Diabetes Care·UNKNOWN American Diabetes Association
Feb 19, 2008·Journal of the American College of Cardiology·Michael MillerUNKNOWN PROVE IT-TIMI 22 Investigators
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Oct 30, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Jean-Charles FruchartUNKNOWN Residual Risk Reduction Initiative (R3I)
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group

❮ Previous
Next ❯

Citations

Nov 2, 2011·Internal and Emergency Medicine·Alberto Zambon
Oct 5, 2011·Current Cardiology Reports·Beatriz G Talayero, Frank M Sacks
Jan 28, 2014·Cardiovascular Diabetology·Jean-Charles FruchartUNKNOWN Residual Risk Reduction Initiative (R3i)
Feb 11, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Jan BorénMarja-Riitta Taskinen
Dec 3, 2014·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Jesús Millán Núñez-CortésUNKNOWN Residual Risk Reduction Initiative y Grupo de Trabajo sobre Dislipemia Aterogénica
Mar 15, 2016·European Journal of Nutrition·Wiraphol PhimarnKritsanee Saramunee
Jun 22, 2011·Kidney & Blood Pressure Research·Christoph Wanner, Vera Krane

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.